Immunotherapy: Immune-modified response criteria — an iterative learning process?

Immunotherapy: Immune-modified response criteria — an iterative learning process?, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.36

Patients with solid tumours can have unusual patterns of response to anticancer immunotherapy, necessitating the adaptation of traditional response criteria. A recent retrospective analysis of data from patients with four different types of solid tumours treated with the anti-programmed cell death 1 ligand 1 (PD-L1) antibody atezolizumab confirms the previous experience in patients with melanoma and provides several new insights.

中文翻译：

---

免疫疗法：免疫改良的反应标准-迭代学习过程？

免疫疗法：免疫改良的反应标准-迭代学习过程？

免疫疗法：免疫修饰的反应标准-迭代学习过程？，在线发布：2018年3月13日；doi：10.1038 / nrclinonc.2018.36

实体瘤患者对抗癌免疫疗法的反应可能会异常，需要适应传统的反应标准。最近对使用抗程序性细胞死亡1配体1（PD-L1）抗体atezolizumab治疗的四种不同类型实体瘤患者的数据进行的回顾性分析证实了黑色素瘤患者的先前经验，并提供了一些新的见解。